BioCryst Pharmaceuticals BCRX Number of plans
Number of plans at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:ShareBasedPaymentArrangementNumberOfPlans.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
As of June 30, 2026, the Company had three stock-based employee compensation plans: the Amended and Restated Stock Incentive Plan (“Incentive Plan”), the Amended and Restated Inducement Equity Incentive Plan (“Inducement Plan”) and the Amended and Restated Employee Stock Purchase Plan (“ESPP”). The Incentive Plan was most recently amended and restated on April 20, 2026 and approved by the Company’s stockholders on June 11, 2026. The Inducement Plan was most recently amended and restated by the Company’s Board of Directors on October 26, 2023. The ESPP was most recently amended and restated by the Company’s Board of Directors on July 7, 2023.
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's number of plans?
- BioCryst Pharmaceuticals (BCRX) reported number of plans of 3 in Q2 2026.
- How has BioCryst Pharmaceuticals's number of plans changed year-over-year?
- BioCryst Pharmaceuticals's number of plans decreased by 0.0% year-over-year, from 3 to 3.
- What does number of plans mean?
- Number of plans as reported by BioCryst Pharmaceuticals Inc.
Ask your AI about BioCryst Pharmaceuticals's number of plans.
Connect your AI assistant and compare it to peers, right in your chat.
